2016
DOI: 10.1200/jco.2015.64.0094
|View full text |Cite
|
Sign up to set email alerts
|

Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection

Abstract: Marking nodes with biopsy-confirmed metastatic disease allows for selective removal and improves pathologic evaluation for residual nodal disease after chemotherapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

8
469
5
29

Year Published

2016
2016
2024
2024

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 667 publications
(511 citation statements)
references
References 22 publications
8
469
5
29
Order By: Relevance
“…It has been shown that when this cohort of patients undergoes SNB, they have an elevated false negative rate (12%), which is potentially lowered on removal of three or more nodes (9%) [18]. If the suspicious nodes are clipped at ultrasound and removed at SNB, then the false negative rate may fall further to less than 2% [19]. The application of a solid ferromagnetic marker -introduced [19,20] into the suspicious nodes -which could subsequently be excised under intraoperative guidance of a handheld magnetometer, would be clinically relevant and avoid technical and logistical difficulties associated with radioactive markers or wires.…”
Section: Future Perspectivementioning
confidence: 96%
See 1 more Smart Citation
“…It has been shown that when this cohort of patients undergoes SNB, they have an elevated false negative rate (12%), which is potentially lowered on removal of three or more nodes (9%) [18]. If the suspicious nodes are clipped at ultrasound and removed at SNB, then the false negative rate may fall further to less than 2% [19]. The application of a solid ferromagnetic marker -introduced [19,20] into the suspicious nodes -which could subsequently be excised under intraoperative guidance of a handheld magnetometer, would be clinically relevant and avoid technical and logistical difficulties associated with radioactive markers or wires.…”
Section: Future Perspectivementioning
confidence: 96%
“…If the suspicious nodes are clipped at ultrasound and removed at SNB, then the false negative rate may fall further to less than 2% [19]. The application of a solid ferromagnetic marker -introduced [19,20] into the suspicious nodes -which could subsequently be excised under intraoperative guidance of a handheld magnetometer, would be clinically relevant and avoid technical and logistical difficulties associated with radioactive markers or wires. Both removal of more nodes and clipping of nodes have not been confirmed in subsequent clinical trials as yet.…”
Section: Future Perspectivementioning
confidence: 99%
“…Ve studii provedené v MD Anderson [11] byla v rámci klinického stagingu odebrána ze suspektních uzlin bio psie a následně byl do nich vložen klip. Studie zkoumala efektivitu nalezení infiltrovaných uzlin pomocí 1. porovnání přítomnosti nádo-rového postižení uzliny s klipem se zbytkem materiálu z AD, 2. užití bio psie SLN a 3. aplikace zrn radioaktivního jódu 125, která byla k uzlině s klipem umístěna 1-5 dní před operací.…”
Section: Studie Z MD Anderson a Cílená Disekce Axily (Tad)unclassified
“…Na základě metaanalýzy studií, které hodnotily parametry užití bio psie SLN u pa cientek po chemoterapii a cN0 onemocnění, byla přijatelná míra falešné negativity stanovena na 10 % [21]. Všechny tři zmíněné studie [6,8,11], které se zabývaly touto problematikou, však vykázaly faleš-nou negativitu vyšší. Bylo tedy konstatováno, že AD není možné u pa cientek s klinicky postiženými uzlinami (cN1) po podané neoadjuvantní chemoterapii nahradit bio psií SLN.…”
Section: Sentinaunclassified
“…The FNR for SN biopsy in patients undergoing surgery as their first cancer treatment has consistently been shown to be less than 5-10%. Whether this low FNR can be replicated in the post-NAC setting was recently reported by investigators from the MD Anderson Cancer Center in the Journal of Clinical Oncology (April 2016) (7). Building on prior trials that measured both the SN identification rate and the FNR after NAC (2-6), a novel approach termed targeted axillary dissection (TAD) was developed to compare its efficacy to accurately stage the axilla compared to SN biopsy alone.…”
mentioning
confidence: 98%